Costing and cost analysis in randomized controlled trials: caveat emptor

Area of Science:

• Health Economics
• Clinical Trial Methodology
• Biostatistics

Background:

• Cost valuation and analysis are critical components of decision-making in randomized controlled trials (RCTs).
• Evaluating costing within RCTs requires understanding specific choices and trade-offs in valuation and analysis.
• A checklist approach is insufficient for assessing the proper evaluation of costs in RCTs.

Purpose of the Study:

• To provide an overview of central issues in cost valuation and analysis for RCTs.
• To highlight the importance of understanding choices and implications in costing for decision-makers.
• To emphasize the need for rigor in cost valuation methods within RCTs.

Main Methods:

• Discusses resource costing, including micro-costing and gross-costing, detailing their respective advantages and limitations.
• Explains the process of identifying resource types and appropriate price weights for accurate cost valuation.
• Reviews statistical analysis techniques for cost data, addressing challenges like skewed distributions and multivariable analysis.

Main Results:

• Resource costing methods (micro- vs. gross-costing) involve trade-offs between specificity and practicality.
• Accurate cost valuation depends on identifying correct resource types and price weights (nationally determined or center-specific).
• Statistical analysis of cost data, particularly using generalized linear models (GLM), requires careful application due to data distribution challenges.

Conclusions:

• Appropriate cost valuation and analysis techniques are essential for the methodological rigor of RCTs.
• Decision-makers must understand the nuances of cost valuation to properly evaluate RCT findings.
• Applying sound economic and statistical principles to costing in RCTs enhances the reliability of cost-effectiveness evidence.